April 2022 in “Medicina estética” Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.
3 citations
,
August 2020 in “Urology Journal” Using 5-alpha reductase inhibitors may increase the risk of mild depression.
5 citations
,
August 2018 in “Sexual Medicine Reviews” 5α-Reductase inhibitors do not consistently increase testosterone levels in the blood.
145 citations
,
November 2017 in “Journal of The European Academy of Dermatology and Venereology” Use minoxidil for hair loss treatment; assess results after 6 months.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
2 citations
,
October 2021 in “Asian Journal of Andrology” Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
February 2024 in “Actas Dermo-Sifiliográficas” Dermatologists recommend oral dutasteride for male hair loss, low-dose oral minoxidil for female hair loss, and a multidisciplinary approach for young patients, with caution during pregnancy.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” 5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
21 citations
,
March 2018 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” Minoxidil, finasteride, and low-level laser light therapy effectively treat hair loss.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
35 citations
,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
14 citations
,
August 2013 in “Facial Plastic Surgery Clinics of North America” Some nonsurgical hair loss treatments are effective, especially if started early.
8 citations
,
August 2021 in “Fertility and Sterility” Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.
8 citations
,
January 2008 in “Journal of Cosmetic and Laser Therapy” Hair transplantation for men has improved, offering natural, lasting results, and may be enhanced by certain medications and future technologies.
1 citations
,
February 2022 in “JAMA Dermatology” Minoxidil and finasteride are FDA-approved treatments for male hair loss, but off-label use of oral minoxidil, dutasteride, and higher doses of finasteride and minoxidil is increasing.
1 citations
,
October 2021 in “Journal of The American Academy of Dermatology” The document concludes that treatments for hair loss in transgender and gender-diverse individuals include topical solutions, oral medications, laser therapy, and hair restoration procedures, with progress assessed after 6-12 months.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
March 2016 in “National Repository of Dissertations in Serbia” Dutasteride is more cost-effective than finasteride for treating benign prostatic hyperplasia in Montenegro.
Topical minoxidil and oral finasteride and dutasteride are the most effective treatments for male and female pattern hair loss, but study quality varies.
April 2019 in “Journal of emerging technologies and innovative research” Early treatment of Female Pattern Hair Loss is important to stop it from getting worse, and various treatments can help, especially in mild to moderate cases.
November 2022 in “Journal of Education, Health and Sport” Combination therapy for hair loss can improve results and reduce side effects.